Boston Scientific Informs Govt of Potential Job Cuts
The company said one injury has been reported and is investigating manufacturing variability in the affected lots.
- Boston Scientific is removing certain Enroute Transcarotid Neuroprotection System catheters from the market due to risks that the arterial sheath tip may separate during use. Customers were instructed to stop using affected devices earlier this month.
- Separately, Boston Scientific's board approved a global restructuring plan on July 21 aimed at cutting costs and optimizing the supply chain. The company expects to reduce annual expenses by about $500 million by late 2029.
- On Wednesday, the company posted second-quarter net sales of $5.44 billion and adjusted earnings of $0.86 per share, beating guidance. Boston Scientific trimmed full-year profit outlook to $3.28 to $3.32 per share as Watchman demand fell short.
- In Ireland, Boston Scientific informed the Government of potential job cuts at its Galway, Cork, and Clonmel sites. The company filed a collective redundancy notification on July 22 affecting over 7,000 employees across the region.
- The Food and Drug Administration flagged the Enroute device problem on July 24, with Boston Scientific spokesperson Chanel Hastings confirming one reported injury. Complications can include stroke or blood clots, potentially requiring surgical retrieval of the separated tip.
12 Articles
12 Articles
The U.S. medical multinational Boston Scientific approved a restructuring plan that includes the reduction of its workforce. The information in the Restructuring Plan 2026 is indicated in a statement from the U.S. Securities and Exchanges Commission. At this time the company is presenting its financial report for the second quarter. The company has operations in Costa Rica since 2004. Currently based in Alajuela, Heredia and Cartago. The multina…
Boston Scientific's $800 Million Bet: Restructuring Promises Savings but Signals Job Cuts
Boston Scientific just told the world it plans to spend as much as $800 million to become more efficient. The medical device maker’s board signed off on the move July 21. Details landed in a regulatory filing two days later. And the market seemed to like what it saw. Shares rose. Yet buried in the announcement sits a blunt admission. Some employees will lose their jobs. The Marlborough, Massachusetts-based company outlined its 2026 Restructuring…
Boston Scientific unveils new restructuring plan, expects job cuts
Coverage Details
Bias Distribution
- 73% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
